| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/14/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 01/31/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 01/20/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 01/19/2023 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
| 12/09/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/31/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/21/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/06/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
8-K
| Resignation/termination of a director |
| 08/19/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 06/30/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/31/2022 |
8-K
| Quarterly results|
Docs:
|
"Emmaus Life Sciences, Inc. Condensed Consolidated Statement of Operations and Comprehensive Income Year Ended December 31 2021 2020 Revenues, Net $ 20,610 $ 23,167 Cost of Goods Sold 3,312 2,248 Gross Profit 17,298 20,919 Operating Expenses 23,426 20,951 Loss from Operations Total Other Income 1,005 Net Income 1,354 Comprehensive Income 2,577 Earnings per Share $ $ 0.03 Weighted Average Common Shares Outstanding 49,253,156 48,897,004 4 Emmaus Life Sciences, Inc. Condensed Consolidated Balance Sheets" |
|
| 03/31/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/16/2022 |
SC 13D/A
| Niihara Yutaka reports a 26.6% stake in Emmaus Life Sciences, Inc. |
| 01/10/2022 |
8-K
| Appointed a new director |
| 12/30/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/01/2021 |
SC 13D/A
| Niihara Yutaka reports a 26.3% stake in Emmaus Life Sciences, Inc. |
| 11/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|